iRhythm Holdings, a digital healthcare company specializing in disease detection and prevention, announced its participation in three upcoming investor conferences: Jefferies Global Healthcare Conference in London on November 19, 2026, Evercore Healthcare Conference on December 1, 2026, and Citi’s Global Healthcare Conference on December 2, 2026. These presentations will be available via live and archived webcasts on the company’s investor website. This participation highlights iRhythm's efforts to engage with investors and showcase its innovations in wearable biosensors and data analytics for heart health.
iRhythm Holdings' upcoming investor conference participation is presented here with Pluang's Health-sector market snapshot as of Nov 06, 2026 20:42 WIB: Among 150 priced US Health stocks, 51 rose and 94 fell. TransMedics Group Inc (TMDX) gained 11.93% with 100% buy orders and a typical hold time of 26 days, contrasting with DENTSPLY SIRONA Inc (XRAY) which dropped 13.97% and Brookdale Senior Living Inc (BKD) down 11.66%, both with longer hold times of 74 and 22 days respectively.
BriaCell Therapeutics and its subsidiary BriaPro presented positive preclinical data at the SITC 2026 Annual Meeting, highlighting their immunotherapy platforms Bria-OTS+ and BP-80. Bria-OTS+ showed broad immune activation and sustained cancer cell k...
IMUNON, Inc. presented new data from its Phase 2 OVATION 2 trial showing that IMNN-001, combined with chemotherapy, significantly enhances anti-tumor T-cell immune responses in advanced ovarian cancer patients. This immune activation correlates with ...
Canary Capital has launched the Canary Staked INJ ETF (INJC) on Nasdaq, providing investors exposure to INJ, the native token of the Injective blockchain. The ETF not only tracks INJ's price but also earns staking rewards from the network's proof-of-...
The Ozempic market, valued at $30.04 billion in 2026, is projected to grow to $113.95 billion by 2032, with a CAGR of 24.89%. This growth is fueled by increasing demand for diabetes and metabolic health treatments, wider adoption of GLP-1 therapies, ...
Minerva Neurosciences announced its third quarter 2026 financial results and business updates, highlighting progress in its Phase 3 trial of roluperidone, a drug targeting negative symptoms of schizophrenia. The ongoing C19 study aims to confirm prio...
